| Date Filed | Type | Description |
| 10/13/2017 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| DOUMANI ROY (Director) has filed a Form 4 on Kite Pharma, Inc.|
Txns:
| Unknown transaction of 150,620 shares
@ $180, valued at
$27.1M
Disposed/sold 1,807 shares
@ $0
Unknown transaction of 25,065 shares
@ $180, valued at
$4.5M
Disposed/sold 30,000 options to buy
@ $6.89, valued at
$206.7k
Disposed/sold 10,000 options to buy
@ $59.23, valued at
$592.3k
Disposed/sold 7,000 options to buy
@ $50.87, valued at
$356.1k
Disposed/sold 8,810 options to buy
@ $91.21, valued at
$803.6k
|
|
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| JENKINSON PAUL L (CFO) has filed a Form 4 on Kite Pharma, Inc.|
Txns:
| Disposed/sold 9,462 shares
@ $0
Disposed/sold 3,000 shares
@ $180, valued at
$540k
Disposed/sold 41,666 options to buy
@ $45.04, valued at
$1.9M
Disposed/sold 83,334 options to buy
@ $45.04, valued at
$3.8M
Disposed/sold 24,200 options to buy
@ $46.09, valued at
$1.1M
|
|
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/05/2017 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 10/03/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/03/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/03/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/03/2017 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 10/03/2017 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 10/03/2017 |
8-K
| Quarterly results |
| 10/03/2017 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 10/03/2017 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 10/03/2017 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 09/27/2017 |
4
| Tomasello Shawn (Chief Commercial Officer) has filed a Form 4 on Kite Pharma, Inc.|
Txns:
| Granted 4,500 shares
@ $0
Sold 4,203 shares
@ $179.6639, valued at
$755.1k
|
|
| 09/27/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/27/2017 |
4
| MOORE TIMOTHY L. (EVP, Technical Operations) has filed a Form 4 on Kite Pharma, Inc.|
Txns:
| Sold 7,511 shares
@ $83.31, valued at
$625.7k
Granted 8,000 shares
@ $0
Sold 4,228 shares
@ $179.6639, valued at
$759.6k
|
|
| 09/27/2017 |
4
| Wiezorek Jeffrey (SVP Clinical Development) has filed a Form 4 on Kite Pharma, Inc.|
Txns:
| Granted 10,000 shares
@ $0
Sold 5,283 shares
@ $179.6639, valued at
$949.2k
|
|
| 09/27/2017 |
4
| Chang David D (EVP, R&D, Chief Medical Off.) has filed a Form 4 on Kite Pharma, Inc.|
Txns:
| Granted 15,000 shares
@ $0
Sold 7,927 shares
@ $179.6639, valued at
$1.4M
|
|
|